About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 125761, 9 pages
Review Article

Eurycoma longifolia: Medicinal Plant in the Prevention and Treatment of Male Osteoporosis due to Androgen Deficiency

Department of Pharmacology, Faculty of Medicine, The National University of Malaysia, Kuala Lumpur Campus, 50300 Kuala Lumpur, Malaysia

Received 26 April 2012; Accepted 6 June 2012

Academic Editor: Ima Nirwana Soelaiman

Copyright © 2012 Nadia Mohd Effendy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Osteoporosis in elderly men is now becoming an alarming health issue due to its relation with a higher mortality rate compared to osteoporosis in women. Androgen deficiency (hypogonadism) is one of the major factors of male osteoporosis and it can be treated with testosterone replacement therapy (TRT). However, one medicinal plant, Eurycoma longifolia Jack (EL), can be used as an alternative treatment to prevent and treat male osteoporosis without causing the side effects associated with TRT. EL exerts proandrogenic effects that enhance testosterone level, as well as stimulate osteoblast proliferation and osteoclast apoptosis. This will maintain bone remodelling activity and reduce bone loss. Phytochemical components of EL may also prevent osteoporosis via its antioxidative property. Hence, EL has the potential as a complementary treatment for male osteoporosis.

1. Introduction

Traditional medicine is defined by the World Health Organization as the sum total of knowledge, skills, and practices based on the theories, beliefs, and experience indigenous to different cultures that are used to maintain health, as well as to prevent, diagnose, improve, or treat physical and mental illnesses [1]. It covers numerous alternatives that vary from country to country and is referred to as “alternative” or “complementary” medicine. Traditional medicine comprises of biologically based therapies (e.g., herbs and vitamins supplement), manipulative and body-based therapies (e.g., massage and reflexology), mind-body medicine (e.g., meditation), and holistic medical systems, such as acupuncture and ayurveda [2].

For centuries, medicinal plants (i.e., herbal medicine) have been a part of cultural heritage. More than 35,000 plant species have been reported to be used in various human cultures around the world for medicinal purposes [3]. Burkill, in his extensive compilation of economic products of the Malay peninsula, recorded not less than 1,300 plants, which were used in traditional medicine [4]. In spite of the great advances observed in modern medicine in recent decades, plants still make an important contribution to health care. Nowadays, medicinal plants play a significant role as an alternative medicine due to the damaging effects of food processing, environment, and hazardous side effects of prolonged medications [5, 6].

The earliest report on medicinal plant research in Malaysia was on the phytochemical screening of 205 plants in Sabah [7, 8], followed a few years later by the screening of 200 plant species in Peninsular Malaysia for the presence of alkaloids [9]. Subsequently, more plants were screened chemically for alkaloids, saponins, triterpenes, and steroids [10] to the extent of becoming the focus of major worldwide attention currently. Malaysia is rated as one of the 12 countries in the world with mega diversity of plants [11, 12].

According to a WHO global survey report, Malaysia was one of the nine countries that contributed a large amount of sales in herbal medicine worldwide between the year of 1999 to 2001, as seen in Figure 1 [13]. In 2008, the Malaysian market for herbal and natural products was estimated to worth approximately RM10 billion, increasing at the rate of 8% per year. Hence, it was projected that by 2050, the global market for herbal products would be around 5 US trillion dollars [14]. Examples of famous Malaysian medicinal plants are Eurycoma longifolia Jack (Tongkat Ali), Labisia pumila (Kacip Fatimah), Piper sarmentosum (Daun kaduk), Ficus deltoidea (Mas cotek), and Centella Asiatica (Pegaga). These herbs are known to exert antibacterial, antipyretic, antioxidant, anti-inflammatory, and potential antitumor activities [1517].

Figure 1: Sales of herbal medicine of nine representative countries. It is shown that between 1999 and 2001 alone, the sales value of herbal medicines in this group of countries increased by more than 40%. (Source: [13]). Growth in the sales of herbal medicines in a group of nine representative countries, 1999–2001 (Bhutan, Canada, the Czech Republic, Iran, Madagascar, Malaysia, Pakistan, Sudan, and Sweden).

2. Eurycoma longifolia Jack

Eurycoma longifolia Jack (EL) or commercially known as Tongkat Ali in Malaysia, Pasak bumi in Indonesian, Piak and Tung saw in Thailand, and Cay ba binh in Vietnam [18] is a famous medicinal plant in the family of Simaroubaceae. Besides EL, there are three other plant species also known locally as Tongkat Ali which literally means “Stick of a man” and “Ali” of which referring to its aphrodisiac property. The three plant species are Entomophthora apiculata, Polyathia bullata, and Goniothalamus sp. [19, 20]. However, EL is the most widely used species for its therapeutic activities. In Malaysia, EL is well known among various ethnic groups for treating disease and enhancing health, particularly sexual health among men. EL is a shrub tree that grows up to 10 metres in height, with long leaves that are green in colour. The leaves are pinnate in shape (i.e., the leaflets are arranged in pairs) [21]. The flowers of this tree are dioecious, whereas its ovoid-shaped fruits will turn to dark brown colour when they are ripe [22]. Due to the high demand of EL for its tremendous health benefits, EL preparations are now widely available in the health-food market in the form of raw crude powder where the root is dried and grinded without involving any other chemical processing steps.EL is also available in the form of capsules which may either contain raw crude powder or standardised EL extract. EL extract is prepared by extracting the active ingredients, adjusting the preparation to a defined content of a constituent, and followed by concentrating it to a standard level. Other than that, EL is available as an additive brewed with coffee and even canned processed drinks [23, 24]. It has been recommended that EL should be administered orally, as other means such as intraperitoneal could enhance its toxicity by approximately 100-fold [25].

A wide range of chemical compounds have been isolated, especially from the root of EL, which include eurycomanone, eurycomanol, eurycomalactone, canthine-6-one alkaloid, 9-hydroxycanthin-6-one, 14,15β-dihydroxyklaineanone, phenolic components, tannins, quanissoids, and triterpenes, as depicted in Figure 2 [26, 27]. Due to the presence of these chemical compounds, the root has been reported to have effective medicinal values in terms of sexual enhancement property for males, as well as antipyretic, antimalarial, antibacterial, and antitumor properties [28, 29]. EL has been well documented to exert antioxidative properties due to its high concentrations of superoxide dismutase (SOD) [30, 31]. EL is famously known for its aphrodisiac effect, which is due to its ability to stimulate the production or action of androgen hormones, especially testosterone. Hence, it can be used as an alternative for testosterone replacement therapy [21] in a variety of related conditions, for example, in the treatment of male osteoporosis due to androgen deficiency [32].

Figure 2: Some of the chemical constituents isolated from the root of Eurycoma longifolia Jack (Source: [27]).

To the best of our knowledge, till date, there is no reliable review on the effects of Eurycoma longifolia Jack on bone remodeling and its antiosteoporotic value. Hence, this review focused on the effects of Eurycoma longifolia Jack on bone and its postulated antiosteoporotic mechanisms in treating osteoporosis due to androgen deficiency. This information will be useful and applicable for future researches on osteoporosis and the development of a more comprehensive natural medicine approach to bone diseases.

3. Osteoporosis

The incidences of osteoporosis and osteoporosis-related fractures are increasing and have now become a major public health issue. According to the World Health Organization (WHO), osteoporosis occurs if the bone mineral density is more than 2.5 standard deviation below the peak bone mass reference standard for young women. If a similar criterion is used for men in United States (by referring to the peak bone mass reference standard for young men, instead for young women), approximately 1-2 million men may have osteoporosis and another 8–13 million may have osteopenia [33].

Osteoporosis is categorized as one of the serious chronic diseases that has become a significant socioeconomic burden in many countries. Chronic diseases are a major factor in the continuous growth of medical care spending [34]. According to the WHO, chronic diseases are by far the leading cause of mortality in the world [35]. Osteoporosis is a silent, slowly progressive systemic skeletal disease that is characterized by low bone mass and microarchitectural deterioration of bone tissue. It does not usually present with a significant symptom until a bone fracture occurs, hence, the so-called “silent” disease [36]. Therefore, an acute condition due to bone fracture may occur, although osteoporosis is classified as a chronic disease due to its slow and destructive progression. There are two types of this disease: primary and secondary osteoporosis. Primary osteoporosis can be caused by aging and hormonal disturbance. It is also known as senile osteoporosis or postmenopausal osteoporosis, which mainly affects women [37]. On the other hand, secondary osteoporosis is caused by exogenous factors. These include diseases affecting bone metabolism, such as Cushing’s disease, hyperparathyroidism, and liver disease. Medications, such as steroid (prednisone), barbiturates, thyroxine, heparin, and diabetic medications, may also impair bone metabolism, leading to bone loss [38].

Bone is continuously remodelled throughout life, whereby bone resorption activity by osteoclasts is always followed by bone formation by osteoblasts in a perpetual cycle [39]. Osteoporosis occurs when the bone formation and bone resorption cycle is impaired. The resorption and reversal phases of bone remodelling are short, while the period required for osteoblastic replacement of the bone is long. Therefore, any factors that increase the rate of bone remodelling, such as hormonal deficiency, will result in loss of bone mass [40].

The sex hormones, androgen and estrogen, play an important role in regulating bone health. Androgens are the most abundant circulating sex steroids in both men and women that modulate bone remodelling cycle through direct androgenic activity via androgen receptor (AR) or indirect action through aromatization to estrogens [41]. Testosterone is the main androgen and predominant sex steroid in men. About 60–70% of testosterone is bound to sex-hormone binding globulin (SHBG), while the remaining proportion is free and biologically active [42]. Free testosterone can be converted to a more potent AR activator, dihydrotestosterone (DHT) via 5α-reductase enzymes [43]. DHT act by stimulating osteoblast proliferation and enhancing osteoblast differentiation, which will subsequently increase bone formation rate [44]. It can also exert pro-apoptotic effects on osteoclasts that will increase the rate of osteoclast death and indirectly reduce bone resorption activity [45, 46]. Free testosterone can be converted to estrogen via aromatase enzyme found on several tissues including adipose tissue [47] and osteoblastic cells [48, 49].

Estradiol will then activate estrogen receptors (ERs), mainly ERα receptors, which are located on osteoblasts and osteoclasts. Aromatization of androgen is important as estrogen plays a significant role not only in female, but also in male skeletal homeostasis [50, 51]. Osteoporosis is associated with various inflammatory conditions such as rheumatoid arthritis, haematological diseases, and inflammatory bowel disease. Proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-7, and tumor necrosis factor (TNF)-α are elevated in these conditions [52]. They mediate osteoclastogenesis by stimulating osteoclast differentiation and inhibiting apoptosis of osteoclast progenitors [53, 54]. Estrogen promotes the downregulation of these proinflammatory cytokines which stimulate the apoptosis of osteoclasts [55]. Receptor activator of NF-κβ ligand (RANKL) plays a crucial role in osteoclasts formation. Estrogen is able to suppress RANKL production by osteoblast-lineage cells and T and B cells [56], which consequently causes the inhibition of bone resorption by osteoclasts. Other than that, estrogen also stimulates the production of osteoprotegerin (OPG), a potent antiosteoclastogenic factor. This factor blocks the binding of RANK (which is expressed on the osteoblast progenitors) to its ligand (RANKL), thus, making it a potent antagonist of osteoclastogenesis [57].

4. Androgen-Deficient Male Osteoporosis

Males have bigger bones and a higher amount of cortical bones than females. This might be contributed by the stimulatory effects of androgen on periosteal modelling drifts and longitudinal bone growth. In contrast, estrogen, the female predominant hormone, suppresses periosteal bone expansion and longitudinal bone growth [58, 59]. Women have a higher risk of osteoporosis due to their lower bone mass and the exposure to tremendous decline of estrogen after menopause, which will lead to aggressive bone loss. Due to their greater bone mass, men usually present with osteoporotic fractures 10 years later than women. Although, once hip fracture has occurred, men have a higher mortality and morbidity rate than women [60]. Hence, osteoporosis in men is now recognized as a significant and important public health issue [61]. The factors involved in the cause of osteoporosis in men include hypogonadism, prolonged-use of glucocorticoid, alcohol consumption, inflammatory arthritis, and family history of osteoporosis. Hypogonadism, which is a reduction in circulating androgen levels or better known as androgen deficiency, is one of the major causes of osteoporosis in most men worldwide [62, 63].

According to the Endocrine Society, approximately four million men of the worldwide population have hypogonadism but less than 200,000 received treatment [64]. Hypogonadism can be classified into primary and secondary hypogonadism. Primary hypogonadism is caused by testicular impairment due to aging and diseases such as Klinefelter’s syndrome and orchitis, while secondary hypogonadism is caused by pituitary and hypothalamic dysfunction. Adult men produce 3 to 10 mg of testosterone daily that is mostly secreted by the testes. Only about 0.05 mg of testosterone and other androgens, such as dihydroepiandosterone (DHEA), DHEA-sulfate, and androstenedione, are secreted by the adrenal glands [65]. As men age, the testosterone levels decrease and SHBG levels increase. Testosterone declines gradually after the age of 40 by 0.4 to 2.6% [66]. The serum free testosterone level of an 80 year-old man is approximately 50% of that in a 20 year-old.

The development and interpretation of animal models are essential for the study of the role of androgen hormone in male skeletal growth. The orchidectomized adult male rat has been widely used as a model for bone studies of androgen-deficient male. According to Gill et al., orchidectomy causes a fall in serum testosterone level by approximately 80% in male rats [67]. This may explain the reduction of lumbar vertebral and tibial bone volume, as well as the reduction of femoral bone mineral density, due to the acceleration of bone remodelling rate as demonstrated in previous studies [68]. Orchidectomy also results in reduced bone strength, body weight, and lean body mass [69, 70]. Recently, Nazrun et al. have shown that orchidectomy causes significant bone calcium loss which is consistent with osteoporosis due to androgen deficiency. In the same study, a bone resorption marker, C-terminal telopeptide of type 1 collagen (CTx), was found to be elevated in the orchidectomized rats [71]. This indicates that androgen plays a major role in male skeletal regulation, whereby orchidectomy may cause bone loss by increasing the bone resorption activity.

The loss of gonadal function also causes an upregulation of osteoclastogenesis by increasing the production of IL-1, IL-6, IL-7, and TNF-α [72], which will result in bone resorption. As the testosterone synthesized by the gonads is the major source of circulating estradiol in males, orchidectomy will not only reduce the testosterone level, but also the estradiol levels [73]. Estrogen withdrawal following androgen deficiency will result in the upregulation of RANKL and downregulation of OPG, resulting in increased osteoclastic activity.

Orchidectomy can also promote the upregulation of reactive oxygen species (ROS), which contribute to oxidative stress [74]. This leads to osteoblast apoptosis and promotion of osteoclast differentiation [75]. Estrogen (mainly estradiol) plays an important role as an antioxidative agent that will upregulate the glutathione reductase activity to combat the deleterious ROS activity. This results in stimulation of osteoclast apoptosis and inhibition of osteoblast apoptosis.

Based on the facts above, we can see that androgen deficiency not only impairs the function of testosterone on bone, but also indirectly impairs estrogen activities. Androgen-deficient osteoporosis has long been treated using testosterone replacement therapy (TRT), which is usually given via intramuscular injection to produce a stable testosterone level as well as improving calcium absorption to reduce bone resorption. TRT is not only painful and prone to cause infection, but its prolonged use may produce harmful side effects, such as prostate cancer, liver damage, cardiovascular diseases, and painful erections [76]. On the other hand, the oral form of testosterone is mostly deactivated by the liver and is associated with liver tumors. Transdermal testosterone in the form of cream and gel may cause transference to women and children by skin contact. This is also the most expensive form as it requires a high concentration of testosterone.

The other treatment options for osteoporosis in men are biphosphonates, which include alendronate and risedronate. These drugs have been shown to significantly reduce the risk of vertebral fracture. However, they can cause many adverse effects, such as abdominal pain, esophageal cancer, jawbone necrosis, muscle pain, and nausea [77]. The Food and Drug Administration (FDA) has also approved recombinant human parathyroid hormone (PTH) for the treatment of androgen-deficient osteoporosis. Several studies have shown that PTH has positive effects on bone turnover rate and significantly increases bone mineral density [78]. However, due to its high cost of treatment and adverse effects, such as marrow fibrosis, headache, and osteosarcoma, PTH should only be considered for men with severe osteoporosis. Another effective medication that is still under an ongoing multicenter international trial is strontium ranelate. Strontium ranelate has been proven to be significantly effective in reducing fractures especially in postmenopausal women by stimulating bone formation activity and simultaneously reducing bone resorption by osteoclasts [79]. Recent studies have found that strontium ranelate is also able to increase bone mineral density in osteoporotic men [80]. Regardless the efficacy of strontium ranelate on improving bone health, it is, however, still has not been approved by FDA and may produce side effects such as nausea, diarrhea, and thrombosis [81]. Among the mentioned available treatments, TRT is widely used in male osteoporosis due to androgen deficiency. Despite the available treatments of osteoporosis, the development of an alternative treatment agent to protect against osteoporosis in men is highly desirable. This alternative agent should ideally be without any side effects and can be easily taken as a supplement.

5. Mechanism of Action of Eurycoma longifolia Jack in the Prevention and Treatment of Osteoporosis

The pharmacological properties of EL have been widely studied. Over the years, pharmacological evaluations of this plant showed that it has antimalarial [82], antibacterial [83, 84], antitumor, and antioxidant [85, 86] properties. Recently, it was established that EL may be used in the prevention and treatment of osteoporosis, or more specifically, male osteoporosis. In the study, it was shown that orchidectomized male rats supplemented with EL did not experience bone calcium loss [32]. The root of EL contains a wide variety of chemical compounds including alkaloids, quassinoids, quassinoid diterpenoids, eurycoma no side, eurycolactone, eurycomalactone, phenolic component, and tannins [87]. Apart from these compounds, a bioactive peptide of 4.3 kDa with aphrodisiac properties has been identified [88]. These phytochemicals may be the reasons behind the effectiveness of EL on various diseases. The underlying mechanism of EL against osteoporosis is still unclear, but studies have demonstrated that it is mainly due to its aphrodisiac property. With regard to the said aphrodisiac property, several animal model studies using rats revealed an increase of sexual motivation and performance along with the increase of serum testosterone concentrations in treated rats [89]. While animal studies do not always guarantee similar results in human, it has been shown that EL supplementation has increased the level of serum testosterone in most subjects in a human study [86].

The bioactive complex polypeptides from the EL root extract, labelled as eurypeptides, can exert and enhance their effects on the biosynthesis of various androgens [90]. Eurypeptides work by stimulating dihydroepiandosterone (DHEA). DHEA will act on androgen receptors to initiate the conversion of androstenedione and androstenediol to testosterone and estrogen, respectively [91]. These eurypeptides may also alleviate SHBG and subsequently increase the free testosterone level [92]. Due to these proandrogen properties of EL, it is able to stimulate osteoblast proliferation and differentiation, resulting in increased bone formation rate. High levels of testosterone and estrogen may also exert proapoptotic effects on osteoclasts, reducing the bone resorptive activity. As testosterone level decreases with age, it has been suggested that men can consume EL (at suitable dosage) as a supplement, to replace the famous proandrogenic drug, sildenafil (or better known as Viagra), which can cause harmful adverse effects [93].

Other than its proandrogenic properties, EL contains high level of nitric oxide (NO) [94] that have effects on bone. NO derived from the endothelial isoform of nitric oxide synthase (eNOS) is widely expressed in bone on a constitutive basis. It acts as a mediator, together with prostaglandin, to promote bone formation and suppress bone resorption [95]. NO in bone cells is stimulated by IL-1 and TNF. At low concentration, NO exerts a destructive effect to potentiate IL-1-induced bone resorption [96]. This effect appears to be biphasic as at high concentrations, NO has been shown to inhibit IL-1- and TNF-α-induced bone resorption [97, 98]. NO is only needed in low concentration to reduce bone resorption and enhance bone formation activity, that is why its short-acting property still makes an impact on bone. Apart from that, NO activity can be upregulated by estradiol [99]. As consumption of EL may increase testosterone level which later will be converted to estradiol, this will indirectly enhance the effect of NO on bone. Van’t Hof and Ralston confirmed that NO is a potent inhibitor of bone resorption via two main mechanisms: by inducing osteoclast apoptosis and by inhibiting mature osteoclast activity [100]. By taking into account the NO effects on bone, the high level of NO in EL can be postulated to be effective in reducing bone resorption activity.

Male osteoporosis can also be explained in terms of oxidative stress mechanism. Free radicals, mainly reactive oxygen species (ROS), are efficiently scavenged in the body. However, oxidative stress will occur when there is an imbalance between increased ROS and inadequate antioxidant activity [101]. Orchidectomy, as shown in the model of androgen-deficient osteoporosis, can promote upregulation of ROS which leads to oxidative stress. Oxidative stress plays a role in osteoblast apoptosis and osteoclast differentiation [102]. Antioxidants such as tocotrienol are known to offer protection against oxidative damage. Tocotrienol can prevent lipid peroxidation by enhancing its glutathione peroxidase (GPx) enzyme activity. Due to its antioxidative property, tocotrienol can protect bone cells from damages caused by lipid peroxidation to maintain bone remodelling [103]. It has been shown that palm vitamin E prevents bone mineral density loss due to orchidectomy [104]. According to Tambi and Kamarul, EL contains high concentrations of superoxide dismutase (SOD), another antioxidant that plays an important role in counteracting oxidative stress [105]. Other components of EL, such as alkaloids and triterpenes, can also act as antioxidants that may reduce bone loss and maintain the bone formation rate.

6. Safety and Toxicity of EL

Although EL has been used in traditional medicine for generations in Malaysia, it was only in the late 1990s that researchers started to pay more attention on its safe dosage and toxicity profile. An acute toxicity study done by Satayavivad et al. has found that the oral Lethal Dose 50 (LD50) of the alcoholic extract of EL in mice is between 1500–2000 mg/kg, while the oral LD50 of the aqueous extract form is more than 3000 mg/kg [106]. Toxicity of EL was further tested by Shuid et al. in their acute toxicity study, where a dose of 5000 mg/kg of EL extract was given orally to rats within 24 hours. It was found that the LD50 for aqueous extract of EL was more than 5000 mg/kg [107]. To extrapolate this animal dosage to human, normalization of body surface area (BSA) method should be used, as shown below [108].

Formula for Dose Translation Based on BSA
Formula for dose translation from animal to human using BSA method (Source: [108])
Hence, EL intake is unlikely to cause fatality in human as the equivalent LD50 for EL is extrapolated to be 810 mg/kg in an adult man. In another subacute toxicity study, EL extract at the doses of 600, 1200, and 2400 mg/kg were given to rats, respectively, for 28 days. Pathological changes in the liver were seen in two rats, each from the group treated with 1200 and 2400 mg/kg. Clinical study in human done by Tambi has found that a dose up to 600 mg/kg did not cause any adverse effects [109]. EL is considered safe as long as it is not taken in high dose. Based on the results of previous toxicity studies, EL is normally recommended to be administered to men at the dose of 200–400 mg daily and should be used with caution, especially in the elderly. Currently, EL is commercially sold worldwide following this established dosage in the form of tablets for easier daily consumption.

7. Conclusion

Based on established literatures on health benefits of EL, it is important to conserve this valuable medicinal plant for the benefit of future generation. There are several mechanisms proposed for its antiosteoporotic effects. The main mechanism is via its testosterone enhancing effects for the prevention and treatment of androgen-deficient osteoporosis. Other mechanisms involved are through its nitric oxide contents and antioxidative properties. Due to its safety profile and potential as an alternative antiosteoporotic agent, further studies are warranted to document a better and conclusive mechanism for its therapeutic action.


The authors would like to thank the National University of Malaysia (UKM) for providing Grant no. UKM-GUP-SK-07-21-202 and the Faculty of Medicine UKM for Grant no. FF-089-2012. The authors are also grateful to Mr. Boekhtiar Borhanuddin for his contribution in editing this paper.


  1. WHO, Traditional Medicine, WHO, Geneva, Switzerland, 2003.
  2. The Star, “Regulating Traditional Medicine,” 2008.
  3. A. Lewington, Medicinal Plants and Plant Extracts: A Review of Their Importation into Europe, Traffic International, Cambridge, UK, 1993.
  4. I. H. Burkill, A Dictionary of Economic Products of the Malay Peninsula, Ministry of Agriculture and Co-operative, Kuala Lumpur, Malaysia, 1966.
  5. P. W. Woods, “Herbal healing,” Essence, vol. 30, pp. 42–46, 1999. View at Google Scholar
  6. WHO, Drug Information. Herbal Medicines, vol. 16, World Health Organization, Geneva, Switzerland, 2002.
  7. M. Elvin-Lewis, “Should we be concerned about herbal remedies,” Journal of Ethnopharmacology, vol. 75, no. 2-3, pp. 141–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. H. R. Arthur, “A phytochemical survey of some plants of North Borneo,” The Journal of Pharmacy and Pharmacology, vol. 6, no. 1, pp. 66–72, 1954. View at Google Scholar · View at Scopus
  9. B. Douglas and A. K. Kiang, “A phytochemical survey of Malaya,” Malayan Pharmaceutical Journal, vol. 6, pp. 1–16, 1957. View at Google Scholar
  10. K. C. Chan, K. F. Mak, and L. E. Teo, “A new phytochemical survey of Malaya. IV. Chemical screening,” Chemical and Pharmaceutical Bulletin, vol. 25, pp. 1826–1829, 1977. View at Google Scholar
  11. Herbal Medicine Research Group, Compendium of Medicinal Plants Used in Malaysia, Kuala Lumpur, Institute for Medical Research, Kuala Lumpur, Malaysia, 2002.
  12. A. R. N. Ismail, “Marketing of medicinal plants using landscape architectural design,” in Proceedings of the Conference on Forestry and Forest Product Research, Medicinal Plants: Quality Herbal Products for Healthy Living (CFFPR'99), pp. 19–25, Forest Research Institute Malaysia (FRIM), 1999.
  13. “National policy on traditional medicine and regulation of herbal medicines,” Report of a WHO Global Survey, World Health Organization, Geneva, Switzerland, 2005.
  14. S. H. Ahmad, Wonder Molecules From Nature and Laboratory, University Publication Centre, Malaysia, 1st edition, 2010.
  15. R. Bhat and A. A. Karim, “Tongkat Ali (Eurycoma longifolia Jack): a review on its ethnobotany and pharmacological importance,” Fitoterapia, vol. 81, no. 7, pp. 669–679, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Zakaria and M. A. Mohd, Traditional Malay Medicinal Plants, vol. 8, Penerbit Fajar Bakti, Kuala Lumpur, Malaysia, 1994.
  17. Z. A. Zakaria, H. Patahuddin, A. S. Mohamad, D. A. Israf, and M. R. Sulaiman, “In vivo anti-nociceptive and anti-inflammatory activities of the aqueous extract of the leaves of Piper sarmentosum,” Journal of Ethnopharmacology, vol. 128, no. 1, pp. 42–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Medicinal Plants, International Technology Center, United Nations International Development Organisation, UNIDO, Trieste, Italy.
  19. M. S. Kamarudin and A. Latiff, Tumbuhan Ubatan Malaysia, Universiti Kebangsaan Malaysia and Ministry of Science Technology and Environment, Malaysia, 2002.
  20. Herbal Medicine Research Group, Compendium of Medicinal Plants Used in Malaysia, vol. 2, Institute for Medical Research, Kuala Lumpur, Malaysia, 2002.
  21. W. G. Goreja, Tongkat Ali: The Tree that Cures a Hundred Diseases, vol. 2, Amazing Herb Press, New York, NY, USA, 2004.
  22. S. H. Goh, C. H. Chuah, J. S. L. Mok, and E. Soepadmo, Malaysian Medicinal Plants for the Treatment of Cardiovascular Disease, Pelanduk Publication, Kuala Lumpur, Malaysia, 1995.
  23. J. B. Jagananth and L.T. Ng, Herbs: The Green Pharmacy of Malaysia, Vinpress Sdn. Bhd. and Malaysian Agricultural Research and Development Institute (MARDI), Kuala Lumpur, Malaysia, 2000.
  24. R. Sahelian, “Tongkat Ali: exotic Asian aphrodisiac,” in Natural Sex Boosters: Supplements that Enhance Stamina, Sensation and Sexuality for Men and Women, R. Sahelian, Ed., p. 87, Square One Publishers, New York, NY, USA, 2004. View at Google Scholar
  25. H. H. Ang, “An insight into Malaysian herbal medicines,” Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 297–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Morita, E. Kishi, K. Takeya, H. Itokawa, and Y. Iitaka, “Squalene derivatives from Eurycoma longifolia,” Phytochemistry, vol. 34, no. 3, pp. 765–771, 1993. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Ismail, N. Ismail, and J. Lassa, Malaysian Herbal Monograph, vol. 1, Malaysian Monograph Committee, Kuala Lumpur, Malaysia, 1999.
  28. J. D. Gimlette and H. W. Thomson, A Dictionary of Malayan Medicine, Oxford University Press, Kuala Lumpur, Malaysia, 1977.
  29. H. H. Ang, Y. Hitotsuyanagi, H. Fukaya, and K. Takeya, “Quassinoids from Eurycoma longifolia,” Phytochemistry, vol. 59, no. 8, pp. 833–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. I. Tambi, “Glycoprotein water-soluble extract of Eurycoma longifolia Jack as a health supplement in management of Health aging in aged men,” in Proceedings of the 3rd World Congress on the Aging Male, B. Lunenfeld, Ed., p. 6, Aging Male, Germany, 2002.
  31. M. I. Tambi, “Standardized water soluble extract of Eurycoma longifolia (LJ100) on men’s health,” International Journal of Andrology, vol. 28, Supplement 1, p. 27, 2005, Proceedings of the 8th International Congress of Andrology, Republic of Korea. View at Google Scholar
  32. A. S. Nazrun, M. Firdaus, A. A. S. Tajul, M. Norliza, M. Norazlina, and N. S. Ima, “The anti-osteoporotic effect of Eurycoma longifolia in aged orchidectomised rat model,” The Aging Male, vol. 14, no. 3, pp. 150–154, 2011. View at Google Scholar
  33. J. P. Bilezikian, “Osteoporosis in men,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 10, pp. 3431–3434, 1999. View at Google Scholar · View at Scopus
  34. C. Roehrig, G. Miller, C. Lake, and J. Bryant, “National health spending by medical condition, 1996–2005,” Health Affairs, vol. 28, no. 2, pp. w358–w367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. WHO, “Chronic diseases,” 2011.
  36. Malaysian Osteoporosis Society.
  37. K. Y. Loh and H. K. Shong, “Osteoporosis: primary prevention in the community,” Medical Journal of Malaysia, vol. 62, no. 4, pp. 355–357, 2007. View at Google Scholar · View at Scopus
  38. S. Lauralee, Fundamentals of Physiology: A Human Perspective, Brooks/Coe Cengage Learning, Canada, 4th edition, 2011.
  39. P. A. Hill, “Bone remodelling,” British Journal of Orthodontics, vol. 25, no. 2, pp. 101–107, 1998. View at Google Scholar · View at Scopus
  40. L. G. Raisz, “Pathogenesis of osteoporosis: concepts, conflicts, and prospects,” Journal of Clinical Investigation, vol. 115, no. 12, pp. 3318–3325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Balasch, “Sex steroids and bone: current perspectives,” Human Reproduction Update, vol. 9, no. 3, pp. 207–222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. N. McGriff-Lee, S. N. Kalantaridou, F. Pucino, and K. A. Calis, “Effects of androgens on bone in men and women,” Clinical Reviews in Bone and Mineral Metabolism, vol. 3, no. 1, pp. 51–66, 2005. View at Google Scholar · View at Scopus
  43. S. H. Windahl, N. Andersson, A. E. Börjesson et al., “Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice,” PLoS One, vol. 6, no. 6, Article ID e21402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Notelovitz, “Androgen effects on bone and muscle,” Fertility and Sterility, vol. 77, no. 4, pp. S34–S41, 2002. View at Google Scholar · View at Scopus
  45. R. L. Jilka, “Cytokines, bone remodeling, and estrogen deficiency: a 1998 update,” Bone, vol. 23, no. 2, pp. 75–81, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. Manolagas, S. Kousteni, and R. L. Jilka, “Sex steroids and bone,” Recent Progress in Hormone Research, vol. 57, pp. 385–409, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. E. R. Simpson, S. E. Bulun, J. E. Nichols, and Y. Zhao, “Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms,” Journal of Endocrinology, vol. 150, pp. S51–S57, 1996. View at Google Scholar · View at Scopus
  48. M. Shozu and E. R. Simpson, “Aromatase expression of human osteoblast-like cells,” Molecular and Cellular Endocrinology, vol. 139, no. 1-2, pp. 117–129, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Tanaka, M. Haji, Y. Nishi, T. Yanase, R. Takayanagi, and H. Nawata, “Aromatase activity in human osteoblast-like osteosarcoma cell,” Calcified Tissue International, vol. 52, no. 2, pp. 107–109, 1993. View at Google Scholar · View at Scopus
  50. B. L. Riggs, S. Khosla, and L. J. Melton, “A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men,” Journal of Bone and Mineral Research, vol. 13, no. 5, pp. 763–773, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Vanderschueren, S. Boonen, and R. Bouillon, “Action of androgens versus estrogens in male skeletal homeostasis,” Bone, vol. 23, no. 5, pp. 391–394, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Ishihara and T. Hirano, “IL-6 in autoimmune disease and chronic inflammatory proliferative disease,” Cytokine and Growth Factor Reviews, vol. 13, no. 4-5, pp. 357–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Girasole, G. Passeri, R. L. Jilka, and S. C. Manolagas, “Interleukin-11: a new cytokine critical for osteoclast development,” Journal of Clinical Investigation, vol. 93, no. 4, pp. 1516–1524, 1994. View at Google Scholar · View at Scopus
  54. R. L. Jilka, R. S. Weinstein, T. Bellido, A. M. Parfitt, and S. C. Manolagas, “Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines,” Journal of Bone and Mineral Research, vol. 13, no. 5, pp. 793–802, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. D. A. Papanicolaou, R. L. Wilder, S. C. Manolagas, and G. P. Chrousos, “The pathophysiologic roles of interleukin-6 in human disease,” Annals of Internal Medicine, vol. 128, no. 2, pp. 127–137, 1998. View at Google Scholar · View at Scopus
  56. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W. J. Boyle, D. L. Lacey, and B. L. Riggs, “Role of RANK ligand in mediating increased bone resorption in early postmenopausal women,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1221–1230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Google Scholar · View at Scopus
  58. R. T. Turner, D. S. Colvard, and T. C. Spelsberg, “Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins,” Endocrinology, vol. 127, no. 3, pp. 1346–1351, 1990. View at Google Scholar · View at Scopus
  59. A. Ornoy, S. Giron, R. Aner, M. Goldstein, B. D. Boyan, and Z. Schwartz, “Gender dependent effects of testosterone and 17β-estradiol on bone growth and modelling in young mice,” Bone and Mineral, vol. 24, no. 1, pp. 43–58, 1994. View at Google Scholar · View at Scopus
  60. G. Poor, E. J. Atkinson, W. M. O'Fallon, and L. J. Melton, “Determinants of reduced survival following hip fractures in men,” Clinical Orthopaedics and Related Research, no. 319, pp. 260–265, 1995. View at Google Scholar · View at Scopus
  61. J. M. Campion and M. J. Maricic, “Osteoporosis in men,” American Family Physician, vol. 67, no. 7, pp. 1521–1525, 2003. View at Google Scholar · View at Scopus
  62. E. S. Orwoll and R. F. Klein, “Osteoporosis in men,” Endocrine Reviews, vol. 16, no. 1, pp. 87–116, 1995. View at Google Scholar · View at Scopus
  63. F. H. Anderson, R. M. Francis, P. L. Selby, and C. Cooper, “Sex hormones and osteoporosis in men,” Calcified Tissue International, vol. 62, no. 3, pp. 185–188, 1998. View at Google Scholar · View at Scopus
  64. “Endocrine Society highlights importance of appropriate diagnosis and treatment of low testosterone,” in Proceedings of the 82nd Annual Meeting of The Endocrine Society, 2000.
  65. D. J. Handelsman, “Androgen action and pharmacologic uses,” in Endocrinology, L. J. DeGroot and J. L. Jameson, Eds., pp. 2232–2242, W. B. Saunders, Philadelphia, Pa, USA, 4th edition, 2001. View at Google Scholar
  66. H. A. Feldman, C. Longcope, C. A. Derby et al., “Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 2, pp. 589–598, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. R. K. Gill, R. T. Turner, T. J. Wronski, and N. H. Bell, “Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor β in rat bone, and reduction is prevented by testosterone,” Endocrinology, vol. 139, no. 2, pp. 546–550, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Gunness and E. Orwoll, “Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats,” Journal of Bone and Mineral Research, vol. 10, no. 11, pp. 1735–1743, 1995. View at Google Scholar · View at Scopus
  69. C. C. Danielsen, L. Mosekilde, and T. T. Andreassen, “Long-term effect of orchidectomy on cortical bone from rat femur: bone mass and mechanical properties,” Calcified Tissue International, vol. 50, no. 2, pp. 169–174, 1992. View at Google Scholar · View at Scopus
  70. M. F. Moreau, H. Libouban, E. Legrand, M. F. Basle, M. Audran, and D. Chappard, “Lean, fat and bone mases are influenced by orchidectomy in the rat. A densitometric X-ray absorptiometric study,” Journal of Musculoskeletal and Neuronal Interactions, vol. 1, no. 3, pp. 209–213, 2001. View at Google Scholar
  71. A. S. Nazrun, A. B. Firdaus, A. A. S. Tajul, M. Norliza, M. Norazlina, and S. Ima Nirwana, “The anti-osteoporotic effect of Eurycoma longifolia in aged orchidectomised rat model,” The Aging Male, vol. 14, no. 3, pp. 150–154, 2011. View at Google Scholar
  72. S. C. Manolagas, R. L. Jilka, G. Girasole, G. Passeri, and T. Bellido, “Estrogens, cytokine and the pathophysiology of osteoporosis,” in Current Opinion in Endocrinology and Diabetes, P. O. Kohler, Ed., pp. 275–281, Current Science, Philadelphia, PA, USA, 1994. View at Google Scholar
  73. R. G. Erben, “Skeletal effects of androgen withdrawal,” Journal of Musculoskeletal and Neuronal Interactions, vol. 1, no. 3, pp. 225–233, 2001. View at Google Scholar
  74. M. S. Almeida, “The basic biology of estrogen and bone,” in Contemporary Endocrinology: Osteoporosis: Pathophysiology and Clinical Management, R. A. Adler, Ed., pp. 333–344, USA, 2002. View at Google Scholar
  75. I. R. Garrett, B. F. Boyce, R. O. C. Oreffo, L. Bonewald, J. Poser, and G. R. Mundy, “Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo,” Journal of Clinical Investigation, vol. 85, no. 3, pp. 632–639, 1990. View at Google Scholar · View at Scopus
  76. N. E. Lane, The Osteoporosis Book: A Guide For Patients and Their Families, Oxford University Press, New York, NY, USA, 2001.
  77. M. J. Favus, “Bisphosphonates for osteoporosis,” New England Journal of Medicine, vol. 363, no. 21, pp. 2027–2035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. D. W. Dempster, F. Cosman, E. S. Kurland et al., “Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study,” Journal of Bone and Mineral Research, vol. 16, no. 10, pp. 1846–1853, 2001. View at Google Scholar · View at Scopus
  79. P. J. Meunier, C. Roux, E. Seeman et al., “The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis,” New England Journal of Medicine, vol. 350, no. 5, pp. 459–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. J. D. Ringe, “Strontium ranelate: an effective solution for diverse fracture risks,” Osteoporosis International, vol. 21, pp. S431–S436, 2010. View at Google Scholar · View at Scopus
  81. S. O'Donnell, A. Cranney, G. A. Wells, J. D. Adachi, and J. Y. Reginster, “Strontium ranelate for preventing and treating postmenopausal osteoporosis,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD005326, 2006. View at Google Scholar · View at Scopus
  82. L. B. S. Kardono, C. K. Angerhofer, S. Tsauri, K. Padmawinata, J. M. Pezzuto, and A. D. Kinghorn, “Cytotoxic and antimalarial constituents of the roots of Eurycoma longifolia,” Journal of Natural Products, vol. 54, no. 5, pp. 1360–1367, 1991. View at Google Scholar · View at Scopus
  83. H. H. Ang and M. K. Sim, “Eurycoma longifolia JACK and orientation activities in sexually experienced male rats,” Biological and Pharmaceutical Bulletin, vol. 21, no. 2, pp. 153–155, 1998. View at Google Scholar · View at Scopus
  84. S. Hamzah and A. Yusof, “The ergogenic effects of Tongkat Ali (Eurycoma longifolia),” British Journal of Sports Medicine, vol. 37, pp. 465–466, 2003. View at Google Scholar
  85. S. Jiwajinda, V. Santisopasri, A. Murakami et al., “In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in Southeast Asia,” Journal of Ethnopharmacology, vol. 82, no. 1, pp. 55–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. M. I. Bin and M. K. Imran, “Eurycoma longifolia Jack in managing idiopathic male infertility,” Asian Journal of Andrology, vol. 12, no. 3, pp. 376–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Bedir, H. Abou-Gazar, J. N. Ngwendson, and I. A. Khan, “Eurycomaoside: a new quassinoid-type glycoside from the roots of Eurycoma longifolia,” Chemical and Pharmaceutical Bulletin, vol. 51, no. 11, pp. 1301–1303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. O. Asiah, M. Y. Nurhanan, and A. Mohd Ilham, “Determination of bioactive peptide (4.3 KDA) as an aphrodisiac marker in six Malaysian plants,” Journal of Tropical Forest Science, vol. 19, no. 1, pp. 61–63, 2007. View at Google Scholar · View at Scopus
  89. H. H. Ang and M. K. Sim, “Eurycoma longifolia increases sexual motivation in sexually naive male rats,” Archives of Pharmacal Research, vol. 21, no. 6, pp. 779–781, 1998. View at Google Scholar · View at Scopus
  90. J. M. Ali and J. M. Saad, Biochemical effect of Eurycoma longifolia Jack on the sexual behaviour, fertility, sex hormone and glycolysis [Dissertation], Department of Biochemistry, University of Malaya, 1993.
  91. M. I. Tambi, M. K. Imran, and R. R. Henkel, “Standardised water-solubleextract of Eurycoma longifolia, Tongkat ali, as testosterone booster for men with late- onset hypogonadism,” Andrologia, vol. 44, pp. 226–230, 2011. View at Google Scholar
  92. H. H. Ang, H. S. Cheang, and A. P. M. Yusof, “Effects of Eurycoma longifolia Jack (Tongkat Ali) on the initiation of sexual performance of inexperienced castrated male rats,” Experimental Animals, vol. 49, no. 1, pp. 35–38, 2000. View at Google Scholar · View at Scopus
  93. S. G. Moreira, R. E. Brannigan, A. Spitz, F. J. Orejuela, L. I. Lipshultz, and E. D. Kim, “Side-effect profile of sildenafil citrate (Viagra) in clinical practice,” Urology, vol. 56, no. 3, pp. 474–476, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Ray, Natural Sex Booster: Supplements That Enhance Stamina, Sensation and Sexuality For Men and Women, Square One Publisher, New York, NY, USA, 2004.
  95. R. J. Van't Hof and S. H. Ralston, “Nitric oxide and bone,” Immunology, vol. 103, no. 3, pp. 255–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. S. H. Ralston, L. P. Ho, M. H. Helfrich, P. S. Grabowski, P. W. Johnston, and N. Benjamin, “Nitric oxide: a cytokine-induced regulator of bone resorption,” Journal of Bone and Mineral Research, vol. 10, no. 7, pp. 1040–1049, 1995. View at Google Scholar · View at Scopus
  97. M. L. Brandi, M. Hukkanen, T. Umeda et al., “Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 7, pp. 2954–2958, 1995. View at Publisher · View at Google Scholar · View at Scopus
  98. C. W. G. M. Lowik, P. H. Nibbering, M. Van de Ruit, and S. E. Papapoulos, “Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption,” Journal of Clinical Investigation, vol. 93, no. 4, pp. 1465–1472, 1994. View at Google Scholar · View at Scopus
  99. K. E. Armour and S. H. Ralston, “Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells,” Endocrinology, vol. 139, no. 2, pp. 799–802, 1998. View at Publisher · View at Google Scholar · View at Scopus
  100. R. J. Van't Hof and S. H. Ralston, “Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1797–1804, 1997. View at Google Scholar · View at Scopus
  101. B. Halliwell and J. M. C. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, New York, NY, USA, 2007.
  102. F. Wauquier, L. Leotoing, V. Coxam, J. Guicheux, and Y. Wittrant, “Oxidative stress in bone remodelling and disease,” Trends in Molecular Medicine, vol. 15, no. 10, pp. 468–477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. H. Xu, B. A. Watkins, and M. F. Seifert, “Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry,” Calcified Tissue International, vol. 57, no. 4, pp. 293–300, 1995. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Ima-Nirwana, A. Kiftiah, A. G. Zainal, M. Norazlina, M. T. Gapor, and B. A. K. Khalid, “Palm vitamin E prevents osteoporosis in orchidectomized growing male rats,” Natural Product Sciences, vol. 6, no. 4, pp. 155–160, 2000. View at Google Scholar · View at Scopus
  105. M. I. Tambi and M. I. Kamarul, “Eurycoma longifolia Jack in managing idiopathic male infertility,” Asian Journal of Andrology, vol. 12, no. 3, pp. 376–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Satayavivad, S. Noppamas, S. Aimon, and T. Yodhathai, “Toxicological and antimalaria activity of Eurycoma longifolia Jack extracts in mice,” Thai Journal of Phytopharmacy, vol. 5, pp. 14–27, 1998. View at Google Scholar
  107. A. N. Shuid, L. K. Siang, T. G. Chin, N. Muhammad, N. Mohamed, and I. N. Soelaiman, “Acute and subacute toxicity studies of Eurycoma longifolia in male rats,” International Journal of Pharmacology, vol. 7, no. 5, pp. 641–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” FASEB Journal, vol. 22, no. 3, pp. 659–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. M. I. Tambi, “Standardized water soluble extract of Eurycoma longifolia (LJ100) on men’s health,” International Journal of Andrology, vol. 28, pp. 25–44, 2005. View at Google Scholar